Genome Medicine (Apr 2022)
Clinical implementation of RNA sequencing for Mendelian disease diagnostics
- Vicente A. Yépez,
- Mirjana Gusic,
- Robert Kopajtich,
- Christian Mertes,
- Nicholas H. Smith,
- Charlotte L. Alston,
- Rui Ban,
- Skadi Beblo,
- Riccardo Berutti,
- Holger Blessing,
- Elżbieta Ciara,
- Felix Distelmaier,
- Peter Freisinger,
- Johannes Häberle,
- Susan J. Hayflick,
- Maja Hempel,
- Yulia S. Itkis,
- Yoshihito Kishita,
- Thomas Klopstock,
- Tatiana D. Krylova,
- Costanza Lamperti,
- Dominic Lenz,
- Christine Makowski,
- Signe Mosegaard,
- Michaela F. Müller,
- Gerard Muñoz-Pujol,
- Agnieszka Nadel,
- Akira Ohtake,
- Yasushi Okazaki,
- Elena Procopio,
- Thomas Schwarzmayr,
- Joél Smet,
- Christian Staufner,
- Sarah L. Stenton,
- Tim M. Strom,
- Caterina Terrile,
- Frederic Tort,
- Rudy Van Coster,
- Arnaud Vanlander,
- Matias Wagner,
- Manting Xu,
- Fang Fang,
- Daniele Ghezzi,
- Johannes A. Mayr,
- Dorota Piekutowska-Abramczuk,
- Antonia Ribes,
- Agnès Rötig,
- Robert W. Taylor,
- Saskia B. Wortmann,
- Kei Murayama,
- Thomas Meitinger,
- Julien Gagneur,
- Holger Prokisch
Affiliations
- Vicente A. Yépez
- Institute of Human Genetics, School of Medicine, Technical University of Munich
- Mirjana Gusic
- Institute of Human Genetics, School of Medicine, Technical University of Munich
- Robert Kopajtich
- Institute of Human Genetics, School of Medicine, Technical University of Munich
- Christian Mertes
- Department of Informatics, Technical University of Munich
- Nicholas H. Smith
- Department of Informatics, Technical University of Munich
- Charlotte L. Alston
- Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University
- Rui Ban
- Institute of Neurogenomics, Helmholtz Zentrum München
- Skadi Beblo
- Department of Women and Child Health, Hospital for Children and Adolescents, Center for Pediatric Research Leipzig (CPL), Center for Rare Diseases, University Hospitals, University of Leipzig
- Riccardo Berutti
- Institute of Human Genetics, School of Medicine, Technical University of Munich
- Holger Blessing
- Department for Inborn Metabolic Diseases, Children’s and Adolescents’ Hospital, University of Erlangen-Nürnberg
- Elżbieta Ciara
- Department of Medical Genetics, Children’s Memorial Health Institute
- Felix Distelmaier
- Department of General Pediatrics, Neonatology and Pediatric Cardiology, Heinrich-Heine-University
- Peter Freisinger
- Department of Pediatrics, Klinikum Reutlingen
- Johannes Häberle
- University Children’s Hospital Zurich and Children’s Research Centre
- Susan J. Hayflick
- Department of Molecular and Medical Genetics, Oregon Health & Science University
- Maja Hempel
- Institute of Human Genetics, University Medical Center Hamburg-Eppendorf
- Yulia S. Itkis
- Research Centre for Medical Genetics
- Yoshihito Kishita
- Diagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research Center, Juntendo University, Graduate School of Medicine
- Thomas Klopstock
- Department of Neurology, Friedrich-Baur-Institute, University Hospital, Ludwig-Maximilians-Universität
- Tatiana D. Krylova
- Research Centre for Medical Genetics
- Costanza Lamperti
- Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) Istituto Neurologico Carlo Besta
- Dominic Lenz
- Division of Neuropediatrics and Pediatric Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg
- Christine Makowski
- Department of Pediatrics, Technical University of Munich
- Signe Mosegaard
- Research Unit for Molecular Medicine, Department of Clinical Medicine, Aarhus University
- Michaela F. Müller
- Department of Informatics, Technical University of Munich
- Gerard Muñoz-Pujol
- Section of Inborn Errors of Metabolism-IBC, Department of Biochemistry and Molecular Genetics, Hospital Clínic, IDIBAPS, CIBERER
- Agnieszka Nadel
- Institute of Human Genetics, School of Medicine, Technical University of Munich
- Akira Ohtake
- Department of Pediatrics & Clinical Genomics, Faculty of Medicine, Saitama Medical University
- Yasushi Okazaki
- Diagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research Center, Juntendo University, Graduate School of Medicine
- Elena Procopio
- Inborn Metabolic and Muscular Disorders Unit, Anna Meyer Children Hospital
- Thomas Schwarzmayr
- Institute of Human Genetics, School of Medicine, Technical University of Munich
- Joél Smet
- Department of Pediatric Neurology and Metabolism, Ghent University Hospital
- Christian Staufner
- Division of Neuropediatrics and Pediatric Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg
- Sarah L. Stenton
- Institute of Human Genetics, School of Medicine, Technical University of Munich
- Tim M. Strom
- Institute of Human Genetics, School of Medicine, Technical University of Munich
- Caterina Terrile
- Institute of Neurogenomics, Helmholtz Zentrum München
- Frederic Tort
- Section of Inborn Errors of Metabolism-IBC, Department of Biochemistry and Molecular Genetics, Hospital Clínic, IDIBAPS, CIBERER
- Rudy Van Coster
- Department of Pediatric Neurology and Metabolism, Ghent University Hospital
- Arnaud Vanlander
- Department of Pediatric Neurology and Metabolism, Ghent University Hospital
- Matias Wagner
- Institute of Human Genetics, School of Medicine, Technical University of Munich
- Manting Xu
- Institute of Neurogenomics, Helmholtz Zentrum München
- Fang Fang
- Department of Pediatric Neurology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health
- Daniele Ghezzi
- Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) Istituto Neurologico Carlo Besta
- Johannes A. Mayr
- University Children’s Hospital, Paracelsus Medical University Salzburg
- Dorota Piekutowska-Abramczuk
- Department of Medical Genetics, Children’s Memorial Health Institute
- Antonia Ribes
- Section of Inborn Errors of Metabolism-IBC, Department of Biochemistry and Molecular Genetics, Hospital Clínic, IDIBAPS, CIBERER
- Agnès Rötig
- Université de Paris, Institut Imagine, INSERM UMR 1163
- Robert W. Taylor
- Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University
- Saskia B. Wortmann
- Institute of Human Genetics, School of Medicine, Technical University of Munich
- Kei Murayama
- Department of Metabolism, Chiba Children’s Hospital
- Thomas Meitinger
- Institute of Human Genetics, School of Medicine, Technical University of Munich
- Julien Gagneur
- Institute of Human Genetics, School of Medicine, Technical University of Munich
- Holger Prokisch
- Institute of Human Genetics, School of Medicine, Technical University of Munich
- DOI
- https://doi.org/10.1186/s13073-022-01019-9
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 26
Abstract
Abstract Background Lack of functional evidence hampers variant interpretation, leaving a large proportion of individuals with a suspected Mendelian disorder without genetic diagnosis after whole genome or whole exome sequencing (WES). Research studies advocate to further sequence transcriptomes to directly and systematically probe gene expression defects. However, collection of additional biopsies and establishment of lab workflows, analytical pipelines, and defined concepts in clinical interpretation of aberrant gene expression are still needed for adopting RNA sequencing (RNA-seq) in routine diagnostics. Methods We implemented an automated RNA-seq protocol and a computational workflow with which we analyzed skin fibroblasts of 303 individuals with a suspected mitochondrial disease that previously underwent WES. We also assessed through simulations how aberrant expression and mono-allelic expression tests depend on RNA-seq coverage. Results We detected on average 12,500 genes per sample including around 60% of all disease genes—a coverage substantially higher than with whole blood, supporting the use of skin biopsies. We prioritized genes demonstrating aberrant expression, aberrant splicing, or mono-allelic expression. The pipeline required less than 1 week from sample preparation to result reporting and provided a median of eight disease-associated genes per patient for inspection. A genetic diagnosis was established for 16% of the 205 WES-inconclusive cases. Detection of aberrant expression was a major contributor to diagnosis including instances of 50% reduction, which, together with mono-allelic expression, allowed for the diagnosis of dominant disorders caused by haploinsufficiency. Moreover, calling aberrant splicing and variants from RNA-seq data enabled detecting and validating splice-disrupting variants, of which the majority fell outside WES-covered regions. Conclusion Together, these results show that streamlined experimental and computational processes can accelerate the implementation of RNA-seq in routine diagnostics.
Keywords